In the second installment of the RSV Roundtable, our panel explains how they are educating patients and parents when it comes to RSV, vaccines and preventive measures, and limited treatment availability.
Welcome to the second episode of our 5-episode series; respiratory syncytial virus (RSV) Roundtable, a collaborative project from Contemporary Pediatrics, Contagion, and Contemporary OB/GYN.
This series discusses several aspects of RSV including incidence rates, vaccines, and immunizations.
In this episode, our panel breaks down disease education and discusses how parents have reacted to the new preventive tools nirsevimab (Beyfortus; Sanofi, Astra Zeneca) and RSVpreF (Abrysvo; Pfizer). In addition, the panel explains how vaccine hesitancy and limited availability of nirsevimab has made an impact this RSV season.
Our panel of clinicians includes:
For the first episode of the RSV Roundtable, click here.